Solid Tumors and Hematologic Malignancy Clinical Trial
Official title:
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
This is an open label, dose escalation study using a 3 + 3 design to determine if INCB024360
(study drug) is safe, well-tolerated and effective in patients with advanced malignancies.
Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28
days before the next group is enrolled and may begin to receive study drug. For subject
safety, the first subject in each cohort will be administered drug for one week before the
next two subjects in the cohort can begin drug administration. Doses will be escalated unless
a dose-limiting toxicity (DLT) is observed in one of three subjects.
An expanded cohort of up to 15 patients may be recruited to further explore safety at the
'maximum tolerated dose' or at a lower, pharmacologically active, dose.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02492789 -
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
|
Phase 1 | |
| Terminated |
NCT02712905 -
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00820560 -
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02355431 -
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
|
Phase 2 | |
| Terminated |
NCT02431260 -
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
|
Phase 1/Phase 2 |